Savara’s (SVRA) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reissued their market outperform rating on shares of Savara (NASDAQ:SVRA) in a report issued on Tuesday morning, Benzinga reports. JMP Securities currently has a $9.00 target price on the stock.

Several other analysts have also recently weighed in on SVRA. HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of Savara in a research note on Tuesday. Oppenheimer raised their target price on Savara from $11.00 to $15.00 and gave the stock an outperform rating in a research note on Wednesday, June 26th. Finally, Guggenheim lifted their target price on Savara from $8.00 to $10.00 and gave the company a buy rating in a research report on Thursday, June 27th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Savara presently has a consensus rating of Buy and a consensus target price of $11.17.

Savara Stock Performance

NASDAQ SVRA opened at $3.99 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The stock’s fifty day moving average is $4.32 and its two-hundred day moving average is $4.45. The firm has a market capitalization of $551.37 million, a P/E ratio of -10.78 and a beta of 0.97. Savara has a fifty-two week low of $3.12 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, research analysts anticipate that Savara will post -0.44 earnings per share for the current year.

Institutional Trading of Savara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after buying an additional 746,407 shares in the last quarter. Wellington Management Group LLP acquired a new position in Savara in the 4th quarter valued at about $9,683,000. Vanguard Group Inc. increased its stake in Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after purchasing an additional 148,673 shares during the period. Swiss National Bank acquired a new stake in shares of Savara during the first quarter worth about $732,000. Finally, Superstring Capital Management LP purchased a new position in shares of Savara in the fourth quarter valued at approximately $3,827,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.